Search the Newsreel

Agriculture & Natural Solutions Acquisition Corp (ANSC) Stock News Today

Cullen/Frost Bankers Inc (CFR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Cullen/Frost Bankers Inc (CFR), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 15 analysts, the stock has a "Hold" rating, with an expected revenue of $609.37M for the next quarter and …

Cullinan Therapeutics (NASDAQ:CGEM) Issues Quarterly Earnings Results

Oculis Holding earnings beat by CHF0.23, revenue topped estimates

Oculis Holding reported second-quarter earnings that surpassed analyst estimates by CHF0.23, with revenue also exceeding expectations at CHF311.14K against a consensus of CHF157.82K. Despite the positive earnings surprise, the company's stock price has seen a significant decline, down -62.070% in the last 3 months …

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Oculis Holding AG (OCS) reported a narrower-than-expected Q2 loss of $0.2 per share, beating the Zacks Consensus Estimate of a $0.48 loss, and surpassed revenue estimates with $0.39 million. Despite this, the company's shares have fallen 39.6% year-to-date, contrasting with the S&P 500's gain, …

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Cullinan Therapeutics announced its second-quarter 2026 financial results and provided a corporate update, highlighting progress in its immunology and oncology pipeline. The company reported promising clinical data for CLN-978 and velinotamig in autoimmune diseases, with Phase 2 studies anticipated to begin in early 2027. …

Hercules Capital, Inc. (NYSE:HTGC) Given Average Recommendation of "Moderate Buy" by Analysts

Analysts have issued a "Moderate Buy" consensus rating for Hercules Capital, Inc. (NYSE:HTGC), with an average 12-month price target of $18.46, surpassing its current share price of $16.73. The company recently reported quarterly earnings of $0.50 per share, exceeding estimates, and increased its quarterly …

4D Molecular Therapeutics, Inc. (FDMT) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive financial information for 4D Molecular Therapeutics, Inc. (FDMT), a late-stage biotechnology company. It includes real-time stock price, historical data, performance metrics against the S&P 500, analyst ratings,

LeMaitre management to meet investors at virtual Aug. 11 event

LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that its management will participate in investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026. The event will be held in a virtual format. The company specializes in devices …

Moleculin Biotech (MBRX) stake capped at 4.99% under Intracoastal warrants

A Schedule 13G filing indicates that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively hold a beneficial ownership of 4.99% in Moleculin Biotech, Inc. (MBRX), amounting to 973,927 shares. This ownership includes shares held directly by Intracoastal and shares issuable upon …

Oculis birtir uppgjör fyrir annan ársfjórðung 2026 og kynnir áfanga í rekstri félagsins

ZUG, Sviss, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Félagið færir nú áherslur sínar yfir á taugaauknlækningar með Privosegtor sem leiðandi þróunarlyf félagsins á síðari stigum klínískrar þróunar í gegnum PIONEER-áætlunina. Í kjölfar jákvæðs pre-IND fundar við Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA), eru möguleikar á …

Oculis Reports Q2 2026 Financial Results and Provides Company Update

Oculis, a global biopharmaceutical company, announced its Q2 2026 financial results, reporting $282.3 million in cash, cash equivalents, and short-term investments, providing a cash runway into the second half of 2029. The company is advancing its neuro-ophthalmology pivot with Privosegtor as a lead late-stage …

Moleculin Biotech, Inc. (MBRX) CFO buys 293,333 shares and 879,999 warrants

Moleculin Biotech, Inc.'s CFO, Jonathan P. Foster, recently purchased 293,333 shares of common stock and 879,999 Series I Warrants in a public offering. These were acquired at a combined price of $0.75 per unit, with each unit comprising one share and three warrants. Following …

Federal Agricultural Mortgage Corporation (AGM-A) stock price, news, quote and history

Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history

This article provides a detailed overview of Cullinan Therapeutics, Inc. (CGEM), a clinical-stage biopharmaceutical company focused on autoimmune diseases and cancer. It includes current stock price, historical data, financial metrics, analyst ratings, and a company profile highlighting its drug development pipeline. The company's stock …

LeMaitre Vascular To Go Ex-Dividend On August 20th, 2026 With 0.25 USD Dividend Per Share

LeMaitre Vascular is scheduled to go ex-dividend on August 20th, 2026. The company will be distributing a dividend of $0.25 per share to its shareholders. Investors wishing to receive this dividend should ensure they own shares before the ex-dividend date.

LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

LeMaitre Vascular, Inc. announced its participation in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026, where management will hold investor meetings. The company, a provider of devices for peripheral vascular disease, aims to connect with investors regarding its …

Moleculin Biotech, Inc. (MBRX) CEO adds stock and 1.6M Series I warrants

Moleculin Biotech, Inc.'s CEO, Walter V. Klemp, reported acquiring 533,333 shares of common stock and 1,599,999 Series I warrants in a public offering on August 3, 2026. The purchase was made at a combined price of $0.75 per common share and three accompanying warrants. …

Are You Looking for a Top Momentum Pick? Why Cullen/Frost Bankers (CFR) is a Great Choice

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …

LeMaitre Vascular (LMAT) Hit by Profit Taking

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 …

Here's What Analysts Are Forecasting For Ocular Therapeutix, Inc. (NASDAQ:OCUL) After Its Second-Quarter Results

Ocular Therapeutix (NASDAQ:OCUL) recently released strong second-quarter results, beating revenue expectations and posting smaller-than-anticipated statutory losses. Analysts have slightly increased their optimism regarding per-share losses for 2026, though revenue forecasts remain unchanged. Despite this, the consensus price target of US$27.09 has not shifted, and …

Cullinan to begin potentially registrational acute myeloid leukemia study in Q3

Cullinan Therapeutics reported a Q2 2026 net loss of $53.7 million but maintained a strong cash position of $356 million, providing a runway into 2029. The company announced several upcoming clinical milestones for its immunology and oncology pipeline, including the initiation of a potentially …

LeMaitre Vascular (LMAT) Stock Price Hit By Revenue Guidance Cut

W. R. Berkley (ANSC) discloses 3.27M-share, 9.9% holding in SPAC

W. R. Berkley Corporation, through its subsidiary Berkley Insurance Company, has disclosed a 9.9% beneficial ownership in Agriculture & Natural Solutions Acquisition Corporation (ANSC), a SPAC. This holding amounts to 3,265,181 Class A ordinary shares as of June 30, 2026. The filing indicates shared …

Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Is Cullen/Frost Bankers (CFR) Undervalued On Raised 2026 Earnings Guidance?

LeMaitre Vascular (NASDAQ:LMAT) Sets New 1-Year Low on Analyst Downgrade

LeMaitre Vascular (NASDAQ:LMAT) shares hit a new 52-week low after Wells Fargo downgraded its price target and maintained an equal-weight rating, amidst a broader shift in analyst sentiment to "Hold." The company's Q2 revenue and EPS, despite year-over-year growth, missed analyst expectations, leading to …

LeMaitre Vascular, Inc. Stock 12‑Month Price Target Cut to $116.25, Implies 10% Upside

LeMaitre Vascular, Inc.'s average 12-month price target has been lowered from $118.75 to $116.25 by 8 analysts, suggesting a 10% upside from its Aug. 4 closing price. The consensus rating remains a "Buy" from 9 analysts, with 5 recommending Buy and 4 recommending Hold.

Cullinan Oncology earnings up next: Can pipeline justify cash burn?

Cullinan Therapeutics Inc. is set to report second-quarter earnings, with analysts expecting a wider loss per share. The pre-revenue biotech, with a $1.08 billion market cap, is advancing two late-stage oncology programs, CLN-049 and zipalertinib, which have garnered bullish Wall Street sentiment and significant …

Cullen/Frost Bankers’s Q2 Earnings Call: Our Top 5 Analyst Questions

Cullen/Frost Bankers (CFR) reported Q2 revenue below but non-GAAP profit above analyst expectations, driven by strong customer growth despite challenges in multifamily commercial real estate and increased lending competition. The article highlights key analyst questions from the earnings call, focusing on net interest income …

Cullen/Frost's Branch Expansion Is a Strong Driver for Earnings Growth

Cullen/Frost, a regional bank operating exclusively in Texas, has historically demonstrated resilience through various economic downturns, including energy crises and the coronavirus pandemic. The article highlights that the bank's ongoing branch expansion is a significant contributor to its earnings growth. This strategy, combined with …

Airsculpt Technologies Inc (AIRS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Airsculpt Technologies Inc (AIRS), detailing analyst ratings, price targets, and expected EPS and revenue figures. The current earnings forecast score for AIRS is 6.67, with an average price target of $6.50. Analysts currently have a "Hold" rating …

Federal Agricultural Mortgage (NYSE: AGM) nets 463 shares from SAR exercise

Brian M. Brinch, EVP and Chief Risk Officer of Federal Agricultural Mortgage (AGM), exercised 939 stock appreciation rights (SARs) granted in March 2022. Through net share settlement, he received 463 Class C shares, retaining 238 while 225 shares were withheld for tax obligations and …

LeMaitre Vascular stock hits 52-week low at 79.38 USD

LeMaitre Vascular (LMAT) stock recently hit a 52-week low at $79.38, despite having a strong 1-year return of nearly 25% and being up over 31% year-to-date. The medical device maker is trading below its Fair Value estimate, with analysts setting price targets between $100 …

4D Molecular Therapeutics, Inc. (FDMT) insider sells 26,842 shares under plan

David Kirn, a director and officer at 4D Molecular Therapeutics, Inc. (FDMT), sold 26,842 shares of common stock on August 4, 2026, at a weighted average price of $10.2301 per share. This transaction was conducted under a 10b5-1 trading plan established on January 9, …

Moleculin Biotech (MBRX) CSO buys common stock and Series I Warrants

Moleculin Biotech's Chief Science Officer, Donald H. Picker, recently purchased 173,333 shares of common stock and Series I Warrants to acquire an additional 519,999 shares. These transactions occurred on August 3, 2026, as part of a public offering at a combined price of $0.75 …